About
Freenome is a private biotechnology company headquartered in Brisbane, CA, on a mission to outpace cancer through early detection. By combining cutting-edge multiomics technology with artificial intelligence, Freenome analyzes complex biological signals captured from a routine blood draw to detect cancer in its earliest, most treatable stages — without invasive procedures. Their intelligent screening platform integrates data across multiple biological layers (genomics, proteomics, and more) and applies AI-driven pattern recognition to identify cancer-associated signals with high accuracy. The company's lead program, PREEMPT CRC, is a rigorous clinical study focused on colorectal cancer (CRC) screening, and their SimpleScreen CRC test is designed to make cancer screening more accessible and comfortable for patients. Freenome's approach is backed by a multi-disciplinary team of scientists, clinicians, and engineers, supported by a robust clinical research program that drives discovery, development, and validation of its tests. The platform is designed to integrate with health systems, enabling providers to offer proactive, blood-based cancer screening at scale. Freenome targets health systems, oncology clinics, and clinical research organizations seeking to improve early cancer detection rates. By reducing barriers to screening — replacing or supplementing more invasive methods like colonoscopies — Freenome aims to expand access to life-saving early detection for broader patient populations.
Key Features
- Multiomics-Powered Blood Testing: Analyzes multiple layers of biological data — including genomic, proteomic, and other omics signals — from a single blood draw to detect cancer signatures.
- AI-Driven Cancer Signal Detection: Applies artificial intelligence to identify subtle, cancer-associated patterns in complex biological data, improving detection accuracy at early disease stages.
- PREEMPT CRC Clinical Program: A large-scale, rigorous clinical study designed to validate Freenome's colorectal cancer screening test through real-world patient data and outcomes.
- SimpleScreen CRC Test: A blood-based colorectal cancer screening test that offers a non-invasive alternative or complement to traditional colonoscopy-based screening.
- Health System Integration: Designed to work within existing clinical workflows, enabling health systems and providers to incorporate blood-based cancer screening at population scale.
Use Cases
- Colorectal cancer screening for average-risk patients as a non-invasive alternative to colonoscopy.
- Health system deployment of population-level early cancer detection programs.
- Clinical research and validation studies for blood-based cancer biomarker discovery.
- Supplementing traditional cancer screening workflows with AI-enhanced blood test analysis.
- Improving cancer screening adherence rates by offering a simpler, blood-draw-based option to patients who avoid invasive procedures.
Pros
- Non-Invasive Screening: Uses a standard blood draw rather than invasive procedures, dramatically lowering barriers to cancer screening for patients.
- Early-Stage Detection Focus: Targets detection at the earliest, most treatable cancer stages, when outcomes and survival rates are significantly better.
- Rigorous Clinical Validation: Backed by a comprehensive clinical research program (PREEMPT CRC) with published studies to validate accuracy and reliability.
- Scalable for Health Systems: Built to integrate with health system workflows, enabling broad population-level cancer screening programs.
Cons
- Not Yet FDA-Cleared: SimpleScreen CRC has not yet received FDA clearance or approval, limiting its use to CLIA-certified laboratory settings as of early 2026.
- Currently Limited to Colorectal Cancer: The primary clinical focus is colorectal cancer; broad multi-cancer detection capabilities are still under development.
- Not a Consumer-Facing Product: Freenome's tests are offered through health systems and clinical programs, not directly to individual consumers, limiting access outside partner institutions.
Frequently Asked Questions
What is Freenome's core technology?
Freenome's platform uses multiomics technology — analyzing multiple layers of biological information such as genomic and proteomic data — combined with AI algorithms to detect cancer-associated signals in blood samples taken through a standard blood draw.
Which types of cancer can Freenome detect?
Freenome's current primary focus is colorectal cancer (CRC) through its PREEMPT CRC clinical program and SimpleScreen CRC test. The company's broader platform is designed to be applied to multiple cancer types as research progresses.
Is Freenome's test FDA approved?
As of early 2026, SimpleScreen CRC has not been cleared or approved by the FDA. The test is currently available through Freenome's CLIA-certified clinical laboratory, which is qualified to perform high-complexity clinical testing.
How does the blood test work for cancer screening?
A patient provides a standard blood sample, which is sent to Freenome's clinical laboratory. The sample is analyzed using multiomics technology and AI to detect biological signatures associated with early-stage cancer, and results are reported back to the ordering clinician.
Who is Freenome designed for?
Freenome's solutions are designed for health systems, oncology practices, and clinical research organizations seeking to offer or study blood-based early cancer detection. It is not currently sold directly to individual consumers.
